Skip to main content
. 2018 Nov 2;9(11):1117. doi: 10.1038/s41419-018-1151-3

Fig. 8. TBM enhances chemotherapeutic sensitivity through autophagy modulation.

Fig. 8

a HeLa and SiHa cells were treated with chemotherapeutic drugs, including cisplatin (CDDP, 10 μM), paclitaxel (PTX, 100 nM), doxorubicin (DOX, 0.25 μM) and 5-fluorouracil (5-FU, 2 μM) in the absence or presence of 10 μM TBM for 24 h and MTT assays were performed to assess cell viability. b Cells were treated with CDDP in indicated concentrations for 24 h, and the expression of LC3 and p62 was measured with immunoblot. c HeLa and SiHa cells were treated with 10 μM CDDP in the absence or presence of TBM for 24 h, and the expression of LC3 and p62 was measured with immunoblot. d–e Cells transfected with siScramble, siATG5 or siBeclin1 were co-treated without or with TBM and CDDP, and then subjected to monitor the expression of LC3 II conversion. f Cells transfected with siScramble, siATG5, or siBeclin1 were co-treated without or with TBM and CDDP. Cell viability was determined by MTT assay. *p < 0.05